Apollo Hospitals Enterprise Limited Q4 Result 2024

Synopsis:

Apollo Hospitals Enterprise Limited announced its quarterly results for March 2024 on 30th May after market hours. It reported a consolidated PAT of ₹ 258.40 cr for Q4 FY2024. Its consolidated total revenue for Q4 FY2024 increased by 15.13% on a YOY basis reaching ₹ 4972.00 cr. The company announced a dividend of ₹10 per share for FY2024.

Quarter Result Performance

The company’s total consolidated revenue for Q4 FY2024 was up by 15.13% on a YOY basis, reaching ₹ 4972.00 cr from ₹ 4318.60 cr in Q4 FY2023. The consolidated quarterly revenue was up by 1.92%. Apollo Hospitals Enterprise reported a consolidated PAT of ₹ 258.40 cr for Q4 FY2024 against ₹ 145.60 cr in Q4 FY2023, which is a hike of 77.47%. On a quarterly basis, the consolidated PAT increased by 1.57%. EBITDA increased by 31% ₹ 640 cr.

For the full financial year ending in March 2024, the consolidated PAT stood at ₹ 935.00 cr compared to ₹ 844.30 cr in FY 2023, which is an increase of 10.74%. For FY 2024, its total consolidated revenue stood at ₹ 19165.50 cr compared to ₹ 16702.80 cr in FY 2023, up by 14.74%. EBITDA increased 17% on a YOY basis reaching ₹ 2391 cr. 

Apollo Hospitals Enterprise Limited announced a dividend of ₹10 per share for FY2024.  Additionally, the company appointed Dr Madhu Sasidhar the new President & CEO of its hospital division. 

Apollo Hospitals in FY2024 launched groundbreaking ZAP-X for brain tumour treatment and became the first one to do so in South Asia. The company also introduced the CAR-T cell program and access to Made in India's CAR-T cell therapy, which made it the first hospital to do so in India. 

Apollo’s Healthcare Services (HCS) Revenue witnessed a ₹ 9,867 cr, a 14% YoY increase reaching ₹ 1,365 cr in FY2024. While the 11% YoY growth Apollo Healthco, which includes Pharmacy Distribution & Digital Health witnessed a 17% YOY revenue growth at ₹ 7,827 cr. Its AHLL segment revenue for FY2024 was ₹ 1,365 cr, up by 11% on a YOY basis. 

Commenting on the Q4 results, Dr. Prathap C. Reddy, Chairman, Apollo Hospitals Group said,"FY24 has been a special year for us at Apollo as we achieved some remarkable milestones to further enhance the quality of our care. Our steadfast dedication to delivering top-notch healthcare services continues to be a key pillar of our growth. While Apollo leads the paradigm shift in healthcare focused on prevention of diseases, we are committed to advance our research efforts and leverage cutting-edge, new-age technologies like Al and robotics to enhance patient outcomes.”

“Going forward, Apollo Hospitals will continue to strengthen its endeavors to identify and introduce best-in-class, technology-enabled healthcare solutions to enhance patient outcomes and improve access to quality care. Together, we embark on a journey towards a healthier, more resilient future, where every individual receives the highest standard of care. We are dedicated to contributing to the nation's health agenda through impactful initiatives that address the evolving healthcare needs of our society. We envision a tomorrow where healthcare knows no bounds, and we are steadfast in our commitment to making this vision a reality.” he added. 

About Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited (Apollo Hospitals) is a leading healthcare provider in Asia, known for its comprehensive and integrated healthcare services. Established in 1983 by Dr. Prathap C. Reddy, the company serves patients in diverse specialities such as cardiology, oncology, neurology, orthopaedics, gastroenterology, and more. It also offers advanced treatments like Proton Therapy for cancer, bone marrow transplants, robotic surgeries, minimally invasive cardiac surgeries, and more. Apollo also introduced South East Asia’s first Proton Therapy Centre for cancer treatment in Chennai.